-
1.
公开(公告)号:US20250041447A1
公开(公告)日:2025-02-06
申请号:US18719508
申请日:2022-12-16
Applicant: Cornell University , Health Research, Inc.
IPC: A61K48/00 , A61P35/00 , C12N9/22 , C12N15/11 , C12Q1/6809 , C12Q1/6886 , G16B30/10
Abstract: Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
-
公开(公告)号:US12115215B2
公开(公告)日:2024-10-15
申请号:US18451461
申请日:2023-08-17
Applicant: Health Research, Inc.
Inventor: Yi-Pin Lin , Kaspars Tars
CPC classification number: A61K39/0225 , A61P31/04 , A61K2039/5258 , A61K2039/55566
Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids of SEQ ID NO:1 and one or more adjuvants. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition.
-
公开(公告)号:US20240101701A1
公开(公告)日:2024-03-28
申请号:US18546394
申请日:2022-02-17
Applicant: Health Research, Inc.
Inventor: Leonid CHERKASSKY , Richard KOYA , Kunle ODUNSI , Ben K. SEON
IPC: C07K16/28 , A61K39/00 , C07K14/705 , C07K14/725 , C12N5/0783
CPC classification number: C07K16/2896 , A61K39/4611 , A61K39/4631 , A61K39/464429 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C12N5/0636 , A61K2239/29 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00
Abstract: Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
-
公开(公告)号:US20240009276A1
公开(公告)日:2024-01-11
申请号:US18249816
申请日:2021-10-22
Applicant: Health Research, Inc.
Inventor: Pawel KALINSKI
IPC: A61K38/21 , A61K31/713 , A61P37/04 , A61P31/14 , A61K38/19
CPC classification number: A61K38/212 , A61K31/713 , A61K38/217 , A61P37/04 , A61P31/14 , A61K38/191
Abstract: Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-a) or an inducer thereof, and nuclear factor kappa B (NF-xB) or an inducer or activator thereof.
-
公开(公告)号:US11767303B2
公开(公告)日:2023-09-26
申请号:US17384051
申请日:2021-07-23
Applicant: Health Research, Inc. , Arizona Board of Regents on Behalf of the University of Arizona , Board of Regents, The University of Texas System
Inventor: Hongmin Li , Zhong Li , Jia Zhou , Jimin Xu , Qing-Yu Zhang
IPC: A61K31/5375 , C07D265/30 , C07C233/75 , C07D211/46 , A61P31/14 , C07D409/12 , C07D213/75 , C07D333/54
CPC classification number: C07D265/30 , A61P31/14 , C07C233/75 , C07D211/46 , C07D213/75 , C07D333/54 , C07D409/12
Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.
-
6.
公开(公告)号:US20230173301A1
公开(公告)日:2023-06-08
申请号:US18162995
申请日:2023-02-01
Applicant: Health Research, Inc.
Inventor: Gal Shafirstein , David Bellnier
CPC classification number: A61N5/062 , A61N5/0601 , G01K7/36 , A61N2005/0612 , A61N2005/0628 , A61N2005/063
Abstract: The present disclosure provides a method and a system for treating a tissue using photodynamic therapy (PDT). A photosensitizer is administered to the tissue and one or more optical fibers are placed in the tissue. A treatment light is applied to the tissue by way of the one or more optical fibers. A temperature of the tissue is measured during application of the treatment light, and a fluence rate of the treatment light is modified based on the temperature of the tissue. For example, the fluence rate may be modified to be lower if the temperature of the tissue is higher than a predetermined threshold.
-
公开(公告)号:US20220395494A1
公开(公告)日:2022-12-15
申请号:US17773838
申请日:2020-11-05
Applicant: Health Research, Inc.
Inventor: Scott I. ABRAMS , Sean H. COLLIGAN
IPC: A61K31/47 , A61P35/00 , A61K31/4353
Abstract: Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
-
公开(公告)号:US11491123B2
公开(公告)日:2022-11-08
申请号:US16312316
申请日:2017-06-23
Applicant: HEALTH RESEARCH, INC. , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventor: Hongmin Li , Laura D. Kramer , Zhong Li , Ruili Huang , Menghang Xia
IPC: A61K31/167 , A61K31/426 , A61K31/609 , A61K31/352 , A61K31/409 , A61K31/5415 , A61P31/14 , C07C235/64
Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
-
公开(公告)号:US20220280627A1
公开(公告)日:2022-09-08
申请号:US17705461
申请日:2022-03-28
Applicant: Health Research, Inc.
Inventor: Yi-Pin LIN
Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition
-
公开(公告)号:US20220249531A1
公开(公告)日:2022-08-11
申请号:US17628894
申请日:2020-07-27
Applicant: Health Research, Inc.
Inventor: Andrei BAKIN , Justin ZONNEVILLE
IPC: A61K31/7072 , A61K31/513 , A61K31/5025 , A61K31/502 , A61P35/00
Abstract: Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
-
-
-
-
-
-
-
-
-